WO2023233364 - USE OF ANTI-CLAUDIN-1 ANTIBODIES TO TREAT CHOLANGIOCARCINOMA
National phase entry:
Publication Number
WO/2023/233364
Publication Date
07.12.2023
International Application No.
PCT/IB2023/055667
International Filing Date
01.06.2023
Title **
[English]
USE OF ANTI-CLAUDIN-1 ANTIBODIES TO TREAT CHOLANGIOCARCINOMA
[French]
UTILISATION D'ANTICORPS ANTI-CLAUDINE-1 POUR TRAITER UN CHOLANGIOCARCINOME
Applicants **
ALENTIS THERAPEUTICS AG
UNIVERSITÉ DE STRASBOURG
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
Inventors
BAUMERT, Thomas
MEYER, Markus
IACONE, Roberto
TOSO, Alberto
SCHWEIGHOFFER, Tamas
TEIXEIRA, Geoffrey
MAILLY, Laurent
MULLER, Marion
NEHME, Zeina Hussein
Priority Data
63/365,681
01.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2912 | |
| EPO | Filing, Examination, Granting | 20324 | |
| Japan | Filing, Examination, Granting | 2831 | |
| South Korea | Filing, Examination, Granting | 3453 | |
| USA | Filing, Examination, Granting | 12340 |
Total:
41,860
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to a method of treating a cholangiocarcinoma in a human subject in need thereof, comprising administering a therapeutically effective amount of an anti- Claudin-1 antibody to the human subject.[French]
La présente invention concerne une méthode de traitement d'un cholangiocarcinome chez un sujet humain en ayant besoin, comprenant l'administration d'une quantité thérapeutiquement efficace d'un anticorps anti-claudine-1 au sujet humain.